| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:46 | Corcept's first-in-class ovarian cancer drug gains FDA approval | ||
| 12:46 | FDA opens door to feedback on 'unclear' national priority voucher pathway | ||
| 11:46 | Cognito Therapeutics and Ochsner partner for new brain health approaches | ||
| 10:46 | Daiichi Sankyo and Tempus AI collaborate on ADC clinical development | ||
| Mi | UCB banks on Georgia for $2bn biologics manufacturing facility | ||
| Mi | MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcement | ||
| Mi | Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis | ||
| Mi | MSD and Quotient collaborate on IBD drug targets | ||
| Di | Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout | ||
| Di | Monash University and ClinChoice partner on new therapies development | ||
| Di | Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody | ||
| Mo | Earendil Labs lands $787m to fund biologics development push | ||
| Mo | ImmunityBio receives Macau approval for Anktiva combo therapy | ||
| Mo | BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma | ||
| Fr | Novo Nordisk's Wegovy HD secures FDA greenlight amid patent expiries | ||
| Fr | Novartis to acquire SNV4818 from Synnovation | ||
| Fr | Congruence secures $39.5m to advance small molecule correctors pipeline | ||
| Fr | J&J wins FDA approval for Icotyde to enter psoriasis pill market | ||
| 19.03. | MHRA and NICE launch aligned pathway for faster medicine regulation | ||
| 19.03. | Quintessence debuts first 'living' artificial cell for CGT bio-separation | ||
| 19.03. | Huntington's gene therapy research has reached a turning point, expert says | ||
| 18.03. | Calls for change as access to cell and gene therapies in the Netherlands falls short | ||
| 18.03. | Excalipoint debuts with $68.7m to progress TCE pipeline | ||
| 18.03. | GSK prepared for potential expansion of meningitis vaccine schedule amid UK outbreak | ||
| 18.03. | Navigating the valley of death: a how-to from an investor's perspective |